CBD254-001.pdf
PDF 43 KB Posted
- Solicitation number
- CBD254-001
About this file
This document is a Defense Pricing and Transparency Center (DPTC) solicitation topic for a Small Business Innovation Research (SBIR) contract opportunity.
The Department of Defense seeks technologies and approaches to eliminate cold chain requirements for storage and transportation of medical countermeasures (MCMs), enabling more efficient expeditionary administration through minimized logistics. The contracting effort focuses on Chemical and Biological Defense Program MCMs and encompasses three primary solution categories: thermostabilizing technologies, alternative formulations, and novel routes of administration. The projected CMMC level requirement is N/A, with no Cybersecurity Maturity Model Certification mandated. The modernization priority is Biotechnology, with relevant keywords including cold chain, medical countermeasure, formulation, stability, and temperature-sensitive products.
Phase I requires performers to demonstrate Advanced Development Feasibility through proof-of-concept studies showing technology application, integration into DoD manufacturability and sustainment, regulatory experience or strategy, and a commercialization strategy ensuring long-term DoD access; multiple Phase I awards are anticipated. Phase II requires performers to demonstrate Prototype Feasibility by stabilizing DoD-manufactured MCMs through extended temperature variable trials at 25°C and -40°C for periods of at least six months, ideally one year or more, with efficacy evaluated through in vitro assays, bridging assays, or animal models; multiple Phase II awards are anticipated, and eligible Phase II applicants may apply directly with third-party investor or strategic partner support and USG matched funds. Phase III applications address dual-use civilian healthcare applications where improved cold chain management maximizes healthcare resource utilization, reduces waste, and improves pharmaceutical supply chain stability. No Technical Point of Contact is provided, and no references are included in the solicitation.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| CBD_SBIR_254_R4.pdf |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
CBD254-001: Alternatives to Improve Medical Countermeasure (MCM) Logistics and Administration
PROJECTED CMMC LEVEL REQUIREMENT:
N/A
TECHNOLOGY AREAS:
Chem Bio Defense
MODERNIZATION PRIORITIES:
Biotechnology
KEYWORDS:
Cold chain; medical countermeasure; MCM, formulation; stability; temperature-sensitive
ADDITIONAL INFORMATION
N/A
OBJECTIVE:
Eliminate cold chain requirements for storage and transport of DoD relevant medical countermeasures (MCM).
DESCRIPTION:
The Department of Defense has a need for technologies and approaches to eliminate the cold chain requirements for storage and transportation of medical countermeasures (MCM). This will enable more efficient and expeditionary administration of these critical products through a minimized logistics tail. Existing DoD Chemical and Biological Defense Program developed MCMs will be selected for assessment alongside (1) thermostabilizing technologies, (2) alternative formulations, and or (3) novel routes of administration for long-term MCM efficacy and stability in the absence of cold chain.
PHASE I:
Performers will have demonstrated Advanced Development Feasibility through proof-of-concept studies showing technology application and use. Performers should also demonstrate how their technology integrates into DoD manufacturability and sustainment, as well as their regulatory experience and/or strategy. Lastly, performers will be asked to outline a commercialization strategy that involves long-term DoD access. Multiple awards anticipated.
PHASE II:
Performers will have demonstrated Prototype Feasibility by demonstrating stabilization of DoD-manufactured MCM(s) through exposure to extended temperature variable trials (i.e., 25°C; - 40°C), for periods extending for at least six months and ideally a year or more.). In addition to stability, efficacy of thermostabilized MCMs will be evaluated using appropriate testing that may include in vitro assays, bridging assays demonstrating equivalency or animal models against current MCM formulations. Multiple awards anticipated.
Direct to Phase II: Eligible Phase II applicants may also apply directly to Phase II awards with support from third-party investors or strategic partners and USG matched funds.
PHASE III DUAL USE APPLICATIONS:
Beyond DoD, effective and efficient cold chain management maximizes utilization of healthcare resources, reduces cold chain products wastage, and improves the quality of health services through increased stability of pharmaceutical supply chain and logistics.
REFERENCES:
Not provided by topic author.1.
TECHNICAL POINT OF CONTACT (TPOC):
None
File details come from the government source that posted it. Updated .